Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Description

The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.

Conditions

Breast Cancer, Lymphoma, Hodgkin's Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Commack, Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester, Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau, Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women, 18 years of age and older
  • * Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months
  • * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
  • * Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
  • * Breast cancer patients with any receptor type
  • * English speaking
  • * Able to participate in the informed consent process
  • * Women, 18 years of age and older.
  • * Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months
  • * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
  • * Women with newly diagnosed breast cancer (stage 0-III) who have not yet started treatment and are planning to start Tamoxifen as their only form of systemic treatment within one month
  • * Breast cancer patients with any receptor type
  • * English speaking
  • * Able to participate in the informed consent process
  • * Women, 18 years of age and older.
  • * Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.
  • * Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
  • * Breast cancer patients with any receptor type
  • * English speaking
  • * Able to participate in the informed consent process
  • * Active secondary cancer requiring cytotoxic chemotherapy
  • * Prior systemic treatment for a malignancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Shari Goldfarb, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2025-02